Freedom Investment Management Inc. Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Freedom Investment Management Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 756 shares of the biopharmaceutical company’s stock after selling 118 shares during the period. Freedom Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $795,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. SteelPeak Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the period. Mizuho Securities USA LLC raised its holdings in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the period. Tri Locum Partners LP raised its holdings in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after buying an additional 8,949 shares during the period. Simplify Asset Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after purchasing an additional 3,231 shares during the period. Finally, Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $1,334,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on REGN shares. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Leerink Partners reiterated a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Finally, Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,107.29.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $754.87 on Friday. The company has a market capitalization of $82.95 billion, a P/E ratio of 18.68, a PEG ratio of 2.91 and a beta of 0.15. The company has a 50-day simple moving average of $913.54 and a 200 day simple moving average of $1,020.69. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.